It is still uncertain if the chief executive of embattled Canadian pharmaceutical company Valeant Pharmaceuticals International Inc, Michael Pearson, is to return to the company, his temporary replacement told investors on Wednesday.
The firm’s interim chief executive officer, Howard Schiller, said the company would not now provide any update on the condition of Pearson, who the company said was hospitalized with severe pneumonia just before Christmas last year.
Schiller spoke to a packed room at the JP Morgan Healthcare Conference here in his first public appearance since his appointment.
Schiller said Valeant had been informed by Pearson’s family last week that the timing of his return was uncertain.
It was at that point that the board of directors decided to appoint Schiller — the company’s former chief financial officer — to run the company in Pearson’s absence.
“It truly wasn’t the script or the circumstance under which I would have ever wanted to come back to Valeant,” Schiller , who was the financial officer from 2011 until June last year and is still a director. “Given how I felt about Mike, the company, its prospects and people, it was an easy decision.”
Valeant would not comment on whether Pearson was still hospitalized.
Valeant’s once high-flying stock has plummeted in the past few months as concerns grew about the sustainability of its business model, which has relied in part on acquiring drugs from other firms and sharply raising their prices. It has come under the scrutiny of both the US Congress and US federal prosecutors over its pricing and distribution practices.
Most recently, the company attracted criticism for what had been its secret relationship with a mail-order pharmacy that helped win reimbursement for its costly dermatology drugs. Valeant severed its ties with that pharmacy, Philidor Rx Services, and signed a new agreement with Walgreens.
Schiller said he was “100 percent committed” to the new job, adding that he and Valeant’s management team were “not caretakers” and were “moving things forward.”
“The bottom line is we remain committed to our strategy,” Schiller said. “We are going to regain your trust and confidence.”
Schiller said that Valeant would focus on paying down debt this year rather than spending earnings on its usual large number of acquisitions.
The company, he said, did not anticipate “excessive” price increases on drugs anymore, adding that Valeant needed to devote more resources and attention to relations with investors, governments and the news media.
“We need to change the narrative,” Schiller said.
Valeant shares fell nearly 3 percent on Wednesday, closing at US$85.54. They were briefly above US$260 in August last year.
HEAVY INVESTMENT: Moody’s affirmed the firm’s ‘Aa3’ rating with a ‘stable’ outlook due to its leading position in the industry and ability to match customer requirements Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) revenue this year is expected to increase about 21 percent to NT$1.29 trillion (US$44.01 billion) from NT$1.07 trillion last year, driven by strong demand for advanced 5-nanometer and 7-nanometer chips mainly used in smartphones and high-performance computing devices, a Moody’s Investors Service report on Wednesday said. TSMC’s rate of revenue growth next year is to increase to 7.5 percent, the ratings agency said. The company, which supplies 5-nanometer chips for Apple Inc’s new iPad series, has introduced the advanced chips ahead of its competitors and gained a significant share of the market for the foundry industry’s
NO VIRUS BLUES: A SEMI Taiwan official said that the virus does not slow down the global semiconductor industry’s investment in manufacturing equipment The production value of the nation’s semiconductor industry is expected to grow 16.7 percent this year from last year, outpacing the global industry’s 3.3 percent growth, industry association SEMI said yesterday. That would help Taiwan safeguard its second spot in the global semiconductor market with a production value of more than NT$3 trillion (US$102.73 billion), SEMI Taiwan president Terry Tsao (曹世綸) told a media briefing in Taipei for the Semicon Taiwan trade show beginning today. The global semiconductor industry’s production value is expected to increase to US$426 billion this year, SEMI said. In terms of semiconductor equipment investment, equipment billings from Taiwanese firms
Intel Corp has received licenses from US authorities to continue supplying certain products to Huawei Technologies Co (華為), a company spokesman said yesterday. Washington has been pushing governments around to world to squeeze out Huawei, saying that the telecom giant would hand data to Beijing for espionage. From Monday last week, new curbs have barred US companies from supplying or servicing Huawei. This week, the state-backed China Securities Journal reported that Intel had received permission to supply Huawei. China’s Semiconductor Manufacturing International Corp (SMIC, 中芯國際), which uses US-origin equipment to make chips for Huawei and other companies, last week confirmed that it had sought
Taipei Times: When do you think the hospitality industry can return to how it was before the COVID-19 pandemic? How does Formosa International Hotels Group (FIH, 晶華酒店集團) fare this quarter and beyond? FIH chairman Steve Pan (潘思亮): The virus outbreak will have a serious impact on business travel, driven mainly by meetings, incentive travel, conferences and exhibitions over the past three decades. For the past six months, many businesspeople have grown used to exchanging information on the Internet, where more people can participate. The trend might sustain for three to five years until people are vaccinated and it is safe to